260P - Oncology efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy

Background

Breast cancer in young women has been shown to have an aggressive behavior and poor prognosis. This study aimed to evaluate the outcomes of hormone-receptor (HR)-positive young breast cancer patients treated with neoadjuvant chemotherapy (NAC) and the oncologic efficacy of gonadotropin-releasing hormone (GnRH) agonist.

Methods

This was a retrospective study on a prospectively collected cohort. We included 1123 patients who, between January 2006 and June 2018, were diagnosed with invasive breast cancer and treated with NAC followed by curative surgery at 000. Among patients with HR-positive and human epidermal grow factor 2 (HER2)-negative breast cancer, we analyzed the characteristics and oncology outcomes between the patients equal to or younger than 35 years and the patients older than 35 years.

Results

Among 288 patients with NAC and strong HR-positive/HER2-negative breast cancer, 72 patients were equal to or younger than 35 years of age, and 213 patients were older than 35 years of age. The median follow-up is 74.0 months. There was no statistically significant difference in disease free survival (DFS, p = 0.261) and overall survival (OS, p = 0.625) between the patients equal to or younger than 35 years and the patients older than 35 years. The two groups differed in that the GnRH agonist was used more frequently in the group of patients equal to or younger than 35 years than in the other group (52.4% vs. 11.2%, p<0.001). Interestingly, for the DFS according to the GnRH agonist in the group of patients equal to or younger than 35 years, patients treated with the GnRH agonist had better DFS (p = 0.016).

Conclusions

GnRH agonists might improve the DFS rate of HR-positive/HER2-negative breast cancer in the equal to or younger than 35 years group of patients with NAC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The author.

Funding

Has not received any funding.

Disclosure

The author has declared no conflict of interest.